

Clinical science

# PREDICTIVE POTENTIAL OF THE MELD AND CHILD-TURCOTTE-PUGH II SCORES FOR SBP IN PATIENTS WITH CIRRHOSIS AND ASCITES

Fana Lichoska Josifovikj<sup>1</sup>, Kalina Grivcheva Stardelova<sup>1</sup>, Beti Todorovska<sup>1</sup>, Magdalena Genadieva Dimitrova<sup>1</sup>, Lidija Petkovska<sup>2</sup>, Meri Trajkovska<sup>1</sup>

<sup>1</sup> University Clinic of Gastroenterohepatology; Ss Cyril and Methodius University in Skopje, Faculty of Medicine, Republic of North Macedonia

<sup>2</sup> University Clinic of Toxicology; Ss Cyril and Methodius University in Skopje, Faculty of Medicine, Republic of North Macedonia

**Citation:** Lichoska Josifovikj F, Grivcheva Stardelova K, Todorovska B, Genadieva Dimitrova M, Petkovska L, Trajkovska M. Predictive potential of the MELD and Child-Turcotte-Pugh II scores for SBP in patients with cirrhosis and ascites. Predictive potential of the MELD and Child-Turcotte-Pugh II scores for SBP in patients with cirrhosis and ascites. Arch Pub Health 2021; 15 (2):101-109

doi.org/10.5889/aph.2021.6022

**Key words:** spontaneous bacterial peritonitis (SBP), Child-Turcotte-Pugh II score, MELD score

**\*Correspondence:** Fana Lichoska Josifovikj, University Clinic of gastroenterohepatology, Skopje, Republic of North Macedonia, E-mail: fanil71@yahoo.com

**Received:** 7-Jun-2021; **Revised:** 22-Sep-2021;

**Accepted:** 30-Sep-2021; **Published:** 20-Nov-2021

**Copyright:** © 2021. Fana Lichoska Josifovikj, Kalina Grivcheva Stardelova, Beti Todorovska, Magdalena Genadieva Dimitrova, Lidija Petkovska, Meri Trajkovska. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author(s) and source are credited.

**Competing Interests:** The author have declared that no competing interests

## Abstract

It is very important for patients with spontaneous bacterial peritonitis (SBP) to assess the length of survival and the risk of death, primarily because of the wide range of potential complications that can lead to multisystem organ failure and fatal outcome. The aim of this study was to determine the predictive potential of MELD and Child-Turcotte-Pugh II score for SBP in patients with cirrhosis and ascites. Material and methods: The study was designed as a prospective-analytical-observational and was conducted at the University Clinic for Gastroenterohepatology in Skopje for a period of one year. The study population included 70 hospitalized patients with established liver cirrhosis, regardless of etiology, divided into two groups, 35 patients with SBP and 35 non-SBP. Prognostic scores in patients with liver cirrhosis and ascites: MELD score, according to the formula: MELD =  $[(0.957 \times \text{Ln Creatinin}) + (0.378 \times \text{Ln Bilirubin}) + (1.12 \times \text{Ln INR}) + (0.643) \times 10]$ . The Child-Turcotte-Pugh II score includes 6 parameters: serum albumin and bilirubin, amount of ascites, degree of encephalopathy (HE), prothrombin time (PT) and serum creatinine, and assessment of the degree of hepatic encephalopathy according to the West Haven criteria. Results: The average value of the MELD score in patients with SBP was  $22.6 \pm 8.27$  and in non-SBP the average value was lower -  $17.85 \pm 5.87$ . According to the Mann-Whitney U test, the difference between the mean values was statistically significant for  $p < 0.05$  ( $z = 2.41$ ;  $p = 0.015$ ). A score of 30 to 39 was registered in 25.7% of patients with SBP, and only in 2.9% in non-SBP; the percentage difference was statistically significant for  $p < 0.05$  (Difference test,  $p = 0.0064$ ). Patients with SBP had an average Child-Pugh score of  $13.09 \pm 2.48$  or 100.0% C-class points. In patients with non-SBP, an average child-Pugh score of  $9.65 \pm 1.62$  was recorded, or class B in 65.7% and class C in 34.3%. The percentage difference was statistically significant for  $p < 0.05$  (Difference test,  $p = 0.000000$ ). According to the Mann-Whitney U test, the difference between the mean values was statistically significant for  $p < 0.05$  ( $z = -5.44$ ;  $p = 0.000001$ ). ROC analysis indicated that the Child-Turcotte-Pugh II score contributed to the diagnosis of SBP - 90.7% ( $p = 0.000$ ) (excellent predictor), closer to the ideal value of 1.0 and above the worst value of 0.5. ROC analysis indicated that the MELD score did not contribute to the diagnosis of SBP - 66.7% ( $p = 0.017$ ) (weak predictor), closer to the worst value of 0.5. Conclusion: Our research confirmed that SBP occurs in patients with severe hepatic dysfunction calculated according to the CTP II score and MELD score. Mean value of the MELD score in patients with SBP was higher than in patients with non-SBP. On the other hand all patients with SBP had an average CTP II score, C-class points, while the largest percentage of patients with non-SBP were class B-class points. MELD score is a weak predictor of SBP. The best predictor for predicting SBP is the CTP II score (rank C).

Клинички испитувања

## ПРЕДИКТИВЕН ПОТЕНЦИЈАЛ НА MELD И CHILD-TURCOTTE-PUGH II СКОРОТ ЗА СБП КАЈ ПАЦИЕНТИ СО ЦРНОДРОБНА ЦИРОЗА И АСЦИТ

Фана Личоска Јосифовиќ<sup>1</sup>, Калина Гривчева Старделова<sup>1</sup>, Бети Тодоровска<sup>1</sup>, Магдалена Генадиева Димитрова<sup>1</sup>, Лидија Петковска<sup>2</sup>, Мери Трајковска<sup>1</sup>

<sup>1</sup> Универзитетска клиника за гастроентерохијатологија; Универзитет Св. Кирил и Методиј во Скопје, Медицински факултет, Република Северна Македонија

<sup>2</sup> Универзитетска клиника за токсикологија; Универзитет Св. Кирил и Методиј во Скопје, Медицински факултет, Република Северна Македонија

**Цитирање:** Личоска Јосифовиќ Ф, Гривчева Старделова К, Тодоровска Б, Генадиева Димитрова М, Петковска Л, Трајковска М. Предиктивен потенцијал на MELD и Child-Turcotte-Pugh II скорот за СБП кај пациенти со црнодробна цироза и асцит. Арх. Ј. Здравје 2021;15(2) 101-109

doi.org/10.5889/aph.2021.6022

**Клучни зборови:** спонтан бактериски перитонитис (СБП), Child-Turcotte-Pugh II скор, MELD скор.

**\*Кореспонденција:** Фана Личоска Јосифовиќ, Универзитетска клиника за гастроентерохијатологија; Универзитет Св. Кирил и Методиј во Скопје, Медицински факултет, Република Северна Македонија

E-mail: fanil71@yahoo.com

**Примено:** 7-јун-2021; **Ревидирано:** 22-сеп-2021;

**Прифатено:** 30-сеп-2021; **Објавено:** 20-ное-2021

**Печатарски права:** ©2021 Фана Личоска Јосифовиќ, Калина Гривчева Старделова, Бети Тодоровска, Магдалена Генадиева Димитрова, Лидија Петковска, Мери Трајковска. Оваа статија е со отворен пристап дистрибуирана под условите на нелокализирана лиценца, која овозможува неограничена употреба, дистрибуција и репродукција на било кој медиум, доколку се цитираат оригиналноста(ите) автор(и) и изворот.

**Конкурентски интереси:** Авторот изјавува дека нема конкурентски интереси.

## Извадок

Поради широкиот спектар на потенцијални компликации кои може да доведат до мултисистемско органско попуштање и смрт, многу е важно кај пациентите со спонтан бактериски перитонитис (СБП) да се направи проценка на должината на преживување и ризикот од смртен исход. Целта на трудот беше да се одреди предиктивниот потенцијал на MELD и Child-Turcotte-Pugh II скорот (CTP II) за СБП кај пациентите со црнодробна цироза и асцит. Материјал и методи: Студијата беше дизајнирана како проспективно-аналитичко-опсервациона и се спроведе на Универзитетската клиника за гастроентерохијатологија во Скопје во период од една година. Студиска популација беа хоспитализирани пациенти со етаблирана црнодробна цироза, без оглед на етиологијата, вкупно 70 пациенти, поделени во две групи, 35 пациенти со СБП и 35 без СБП. Прогностички скорови кај пациенти со црнодробна цироза и асцит: MELD скор, според формулата: MELD =  $[(0.957 \times \text{Ln Creatinin}) + (0.378 \times \text{Ln Bilirubin}) + (1.12 \times \text{Ln INR}) + (0.643) \times 10]$ . CTP II скор вклучува 6 параметри: албумин и билрубин во серум, количина на асцит, степен на енцефалопатија, протромбинско време (ПВ) и креатинин во серум, а проценка на степенот на хепатална енцефалопатија(HE) со West-Haven-овите критериуми. Резултати: Просечната вредност на MELD скорот кај пациентите со СБП изнесуваше  $22.6 \pm 8.27$  а кај оние без СБП просечната вредност беше пониска и изнесуваше  $17.85 \pm 5.87$ . Според Mann-Whitney U тестот, разликата помеѓу просечните вредности беше статистички сигнификантна за  $p < 0.05$  ( $z = 2.41$ ;  $p = 0.015$ ). Вредност на скорот од 30 до 39 беше регистрирана кај 25.7% од пациентите со СБП, а само кај 2.9% од оние без СБП; процентуалната разлика беше статистички сигнификантна за  $p < 0.05$  (Difference test,  $p = 0.0064$ ). Кај пациентите со СБП беше регистрирана просечна вредност на CTP II скор од  $13.09 \pm 2.48$  или во поени 100.0%, класа C. Кај пациентите без СБП беше регистрирана просечна вредност на CTP II скорот од  $9.65 \pm 1.62$  или класа B кај 65.7% и класа C кај 34.3%. Процентуалната разлика беше статистички сигнификантна за  $p < 0.05$  (Difference test,  $p = 0.000000$ ). Според Mann-Whitney U тестот, разликата помеѓу просечните вредности беше статистички сигнификантна за  $p < 0.05$  ( $z = -5.44$ ;  $p = 0.000001$ ). ROC-анализата покажа дека CTP II скорот придонесува за дијагностицирање на СБП - 90.7% ( $p = 0.000$ ) (одличен предиктор), поблизу до идеалната вредност од 1.0 и над најлошата вредност од 0.5. ROC-анализата покажа дека MELD скорот не придонесува за дијагностицирање на СБП со 66.7% ( $p = 0.017$ ) (слаб предиктор), поблизу е до најлошата вредност од 0.5. Заклучок: Нашето истражување потврди дека СБП се јавува кај пациенти со тешка хепатална дисфункција пресметана според CTP II и MELD скорот. Средната вредност на MELD скорот кај пациенти со СБП беше поголема отколку кај пациенти со не-СБП. Од друга страна, сите пациенти со СБП имаа просечна вредност на CTP II, С-класа, додека најголем процент од пациентите со не-СБП беа B-класа. MELD скорот е слаб предиктор за СБП. Најдобар предиктор за предвидување на СБП е CTP II (ранг C) скор.

## Introduction

It is very important for patients with spontaneous bacterial peritonitis (SBP) to assess the length of survival and the risk of death, primarily because of the wide range of potential complications that can lead to multisystem organ failure and fatal outcome. Prognostic scores, expressed in numerical values, assess the severity of the current condition using mathematical models and are especially important in transplant medicine (priority for hepatic transplantation).

The Child-Turcotte-Pugh score (CTP score) includes five parameters: albumin and bilirubin in the blood, amount of ascites, degree of hepatic encephalopathy, and prothrombin time (PT)<sup>1-3</sup>. The last three decades have shown that this score is a good prognostic indicator for the survival of patients with alcoholic and posthepatic cirrhosis, primary biliary cirrhosis, primary sclerosing cholangitis, and Budd-Chiari syndrome<sup>4-7</sup>. According to critics, the disadvantage of this score is the inaccuracy that can occur due to the two descriptive parameters: quantification of ascites and hepatic encephalopathy (HE), which values depend on the experience and personal assessment of the examiner. They also stressed that this score is insufficiently accurate in distinguishing the true clinical significance of category C, not including renal laboratory parameters in the evaluation of patients, primarily due to the development of hepatorenal syndrome in patients with terminal disease as a major factor for lethal outcome<sup>8,9</sup>.

In order to overcome these problems, Angermayr et al.<sup>10</sup> performed remodeling of the CTP score by including a new parameter, serum creatinine lev-

el. According to this score, numerical values (points) are added to the baseline values of the CTP score: 0 points for a creatinine value less than 114.92  $\mu\text{mol} / \text{L}$ , 2 points for a creatinine value of 114.92-159.12  $\mu\text{mol} / \text{L}$  and 4 for a creatinine value greater than 159.12  $\mu\text{mol} / \text{L}$ . Analyses showed that the remodeled CTP score was better than the baseline CTP score in predicting HP, but with the same prognostic value in predicting other complications as the baseline CTP score. The significance of the CTP score in terms of survival has been well studied and its grades are: A (5-7 points) - with a median annual survival of 95%, B (7-9 points) - with a median annual survival of 80% and C (10-15 points) - with a median annual survival of 45%<sup>11</sup>.

The MELD Score (Model for End Stage Liver Disease) first appeared in 1999 to assess survival in patients with transjugated portosystem shunt (TIPS)<sup>12</sup>. In the following years the MELD score proved to be a good predictor of short-term survival, a major mortality predictor regardless of etiology and has been officially accepted for assessment of patients undergoing potential cadaveric transplantation<sup>13,14</sup>. In the United States and Europe, this model is used to predict the three-month survival of patients waiting on a liver transplant list<sup>15-17</sup>. According to the original formula, the MELD score is a mathematical formula that includes: serum bilirubin, serum creatinine and INR.  $\text{MELD} = 9.57 \times \ln(\text{creatinine mg} / \text{dl}) + 3.78 \times \ln(\text{bilirubin mg} / \text{dl}) + 11, 2 \times \ln(\text{INR}) + 6.43$ .

Aim of the paper was to determine the predictive potential of MELD and CTP II score for SBP in patients with cirrhosis and ascites.

## Material and methods

The study was designed as a prospective-analytical-observational and was conducted at the University Clinic for Gastroenterohepatology in Skopje for a period of one year. The study population included hospitalized patients with established liver cirrhosis, regardless of etiology; 70 patients, divided into two groups, 35 patients with SBP and 35 non-SBP, with similar demographic characteristics as the SBP group with sterile ascites, in which all variables were examined, as in the study group. The selection of patients who were included in the study was conducted according to pre-determined inclusion and exclusion criteria. Inclusion criteria: patients with cirrhosis of the liver regardless of etiology, age > 18–70 years. Exclusion criteria: age < 18 years, acute liver failure, recent abdominal surgery (< 3 months), infectious pleural effusion, peritoneal carcinomatosis, haemorrhagic ascites (of any origin), hepatocellular carcinoma, immunocompromised patients and those receiving antibiotics for at least 2 weeks prior to enrollment, patients taking non-steroidal anti-inflammatory drugs (NSAIDs), oral contraceptives and anticoagulants.

The study included patients with previously signed informed consent (for the examinations they underwent). Polymorphonuclear cells (PMNC) number was determined directly from the non-centrifuged part of the ascites. 3 ml of fluid was placed in an EDTA test tube to assess the total number of cells and PMN cells, counting by using the Sysmex KxN 21 automatic cell counter-model. Paracentesis was performed under aseptic conditions in a patient placed in a supine position and puncture was made in the left or right lower abdomen

quadrant, with ultrasound imaging (no patient had complications associated with diagnostic paracentesis). All samples for diagnostic testing were immediately sent to the Central Clinical Laboratory. Five mL of ascites was used for automatic counting of PMNK, and at the same time for the needs of biochemical analysis of blood venipuncture of 10 mL of blood was performed. By ultrasonographic examination of the abdomen (ultrasonographic apparatus Samsung Acuson x 300, CH5-2 MHz convex probe), morphological and circulatory disorders within liver cirrhosis were noted. Quantification of ascites was performed by US examination: no ascites, minimum amount of ascites, medium amount of ascites and large amount of ascites. Prognostic scores in patients with liver cirrhosis and ascites: MELD score, according to the formula:  $MELD = [(0.957 \times \ln \text{Creatinine}) + (0.378 \times \ln \text{Bilirubin}) + (1.12 \times \ln \text{INR}) + (0.643) \times 10]$ . The CTP II score includes 6 parameters: serum albumin and bilirubin, amount of ascites, degree of encephalopathy, PV and serum creatinine, and assessment of the degree of hepatic encephalopathy according to the West Haven criteria. Quantification of the degree of hepatic encephalopathy was performed using the West-Haven scale: zero degree (minimal encephalopathy without detectable changes in personality, behavior, memory, concentration, intellectual functions and coordination and asterixis absent). First degree (hypersomnia, insomnia, changes in affect, euphoria, depression, irritability, confusion, slowness), second degree (lethargy, apathy, disorientation in time, visible asterixis, visible change in personality), third degree (somnia, disorientation in time and space, amnesia, more severe confusion, unrelated speech), fourth

degree: coma without response to external stimuli.

Criteria for spontaneous bacterial peritonitis: clinical picture, PMNC number in ascites  $\geq 250$  / 1 mL and / or PMNC number  $< 250$  / in 1 mL ascites fluid, with one bacterial species isolated in microbial culture (CNNA). After prior acquaintance with the structure, content and purpose of the study, as a condition for participation in it, the patients signed the offered informed consent. The study protocol was in line with the ethical principles of the Helsinki Declaration. The protocol and informed consent were submitted for consideration and approved by the Ethics Commission of the Faculty of Medicine at the Ss. Cyril and Methodius University in

Skopje. The collected data was processed using the statistical program SPSS 20 and Statistica for Windows, version 10.

## Results

The mean value of the MELD score in patients with SBP was  $22.6 \pm 8.27$  and in non-SBP the mean value was lower at  $17.83 \pm 5.87$ . According to the Mann-Whitney U test, the difference between the mean values was statistically significant for  $p < 0.05$  ( $z = 2.41$ ;  $p = 0.015$ ). A score of 30 to 39 was registered in 25.7% of patients with SBP, and only in 2.9% of non-SBP; the percentage difference was statistically significant for  $p < 0.05$  (Difference test,  $p = 0.0064$ ) (Tab. 1).

**Table 1.** The prevalence of MELD score in both groups

MELDscore	SBP		Non-SBP	
	N	%	број	%
>40	0		0	
30-39	9	25.7	1	2.9
20-29	12	34.3	13	37.1
10-19	13	37.1	17	48.6
<9	1	2.9	4	11.4
total	35	100.0	35	100.0

Patients with SBP had an average CTP II score of  $13.09 \pm 2.48$  or 100.0% C-class points. In patients with non-SBP, an average CTP II score of  $9.63 \pm 1.62$  was recorded, or class B in 65.7% and class C in 34.3%. The percentage difference was statistically signifi-


cant for  $p < 0.05$  (Difference test,  $p = 0.000000$ ) (Tab. 2). According to the Mann-Whitney U test, the difference between the mean values was statistically significant for  $p < 0.05$  ( $z = -5.44$ ;  $p = 0.00001$ ).



**Table 2.** The prevalence of CTP II score in both groups


points	class	SBP		Non-SBP	
		N	%	број	%
5-6	A	35	100.0	12	34.3
7-9	B				
10-15	C				

ROC analysis indicated that the CTP II score contributed to the diagnosis of SBP - 90.7% ( $p = 0.000$ ) (excellent predictor), closer to the ideal value of 1.0 and above the worst value of 0.5 (Fig. 1).



**Figure 1.** ROC curve of CTP II score as a predictor for SBP

ROC analysis indicated that the MELD score did not contribute to the diagnosis of SBP with 66.7% ( $p = 0.017$ ) (weak predictor), closer to the worst value of 0.5 (Fig. 2).



**Figure 2.** ROC curve of MELD score as a predictor for SBP

## Discussion

The study of prognostic scores in the prediction and prognosis of individual complications of cirrhosis has confirmed their role in clinical practice and simplified access to this vulnerable group of patients. Thanopoulou et al.<sup>17</sup> in their study focused on these clinically simple prognostic assessors. The authors encouraged the introduction of diagnostic paracentesis into the daily routine of all patients with ascites, with the aim of early diagnosis of asymptomatic forms of SBP. Significant prognostic factors for SBP in this study were: the number of PMNCs in ascites, serum bilirubin levels, and renal function status, and the recurrence of SBP depended on the value of the CTP score.

In our study all patients with SBP were categorized in class C on CTP II score (100.0%) with a mean value of  $13.09 \pm 2.40$ , while in the non-SBP group the mean value was  $9.63 \pm 1.26$  (B score: 65.7% and C score: 34.3% ( $p = 0.000000$ )). The mean values of the MELD score in patients with SBP were  $22.60 \pm 8.27$  versus  $17.83 \pm 5.87$  in patients with non-SBP ( $p = 0.0064$ ). The analysis of the results of this segment by our judge can be based on the advantage of the CTP II score over the MELD score in the group of patients with SBP. CTP II contains a calculated amount of ascites and creatinine in serum, and has been shown to be the best predictor of SBP, in contrast to the MELD score which has not been shown to be a good predictor of this condition. According to the ROC analysis, the CTP II score is an excellent predictor of SBP (90.7%) ( $p = 0.000$ ).

Thus, our study confirmed that the MELD score requires additional data on the amount of ascites to become an accurate predictor of ascites-re-

lated conditions and ascites consequences. The prevalence of SBP is higher in patients with severe liver cirrhosis calculated according to the CTP score (class C from 50.3% to 100%), presented in several studies<sup>18-25</sup>. The prospective Haddad 24 study included 148 asymptomatic patients with cirrhosis and refractory ascites. SBP was detected in only 23 patients (3.3%), confirming the low prevalence of SBP in asymptomatic patients with cirrhosis of the liver, while the incidence of SBP was not associated with the severity of liver disease assessed by MELD. Patients on the transplant list have a lower rate of SBP and have significantly higher MELD scores, so the development of SBP is not related to the value of the MELD score but to clinical status and refractory ascites and the need for repetitive paracentesis.

One of the reasons for the low rate of SBP is explained by the fact that in today's conditions, thanks to the appropriate equipment and human resources necessary for proper and successful paracentesis, errors are very rare. Also Zhang et al.<sup>25</sup>, who treated a larger population of patients, did not find any score that would be convincing in the SBP prediction. The study only confirmed that patients with SBP had a higher risk of death than non-SBP. In our analysis, the MELD score proved to be a weak predictor for diagnosing SBP with 66.7% ( $p = 0.017$ ), but several other studies have emphasized its predictive value. Namely, according to them, with each increase of the MELD score, the risk for SBP increases.

Thus, according to Obstein KL. 26 that risk increases by 11%, and according to Gayatri AA. 27 by 30.6%. Some authors even suggested that patients with moderate liver cirrhosis

and ascites with MELD score 20 start a preventive antibiotic treatment 28. Desai et al. 29 focused their research on finding the ideal score that would be predictive of persistent STD. The results showed that the MELD score with values greater than 25 had the highest predictive power compared to other prognostic scores.

## Conclusion

Our research confirmed that SBP occurs in patients with severe hepatic dysfunction calculated according to the CTP II score and MELD score. Mean value of the MELD score in patients with SBP was higher than in patients with non-SBP. On the other hand all patients with SBP had an average CTP II score, C-class points, while the largest percentage of patients with non-SBP were class B-class points. MELD score is a weak predictor of SBP. The best predictor for predicting SBP is the CTP II score (rank C).

## References

1. Child C, Turcotte J. The liver and portal hypertension. In: Child CI, ed. *Surgery and Portal Hypertension*. Philadelphia, USA: W. B. Saunders, 1964: 50–8.
2. Pugh R, Murray-lyon I, Dawson J. Transection of the oesophagus for bleeding oesophageal varices. *Br J Surg* 1973; 60: 646–9.
3. Vorobioff J, Groszmann RJ, Picabea E, et al. Prognostic value of hepatic venous pressure gradient measurements in alcoholic cirrhosis: A 10-year prospective study. *Gastroenterology* 1996;111(3):701-9.
4. Shah DN, Ventura-Cots M, Abral-des JG, et al. Alcohol-related liver disease is rarely detected at early stages compared with liver diseases of other etiologies worldwide. *Clin Gastroenterol Hepatol* 2019;17(11):2320-2329.
5. Planas R, Balleste B, Alvarez MA, Rivera M, Montoliu S, Galeras JA, et al. Natural history of decompensated hepatitis C virus-related cirrhosis. A study of 200 patients. *J Hepatol* 2004;40:823-30.
6. Shetty K, Rybicki L, Carey WD. The Child-Pugh classification as a prognostic indicator for survival in primary sclerosing cholangitis. *Hepatology* 1997;25:1049-53.
7. Zeitoun G, Escolano S, Hadengue A, et al. Outcome of Budd-Chiari syndrome: a multivariate analysis of factors related to survival including surgical portosystemic shunting. *Hepatology* 1999;30:84-9.
8. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application on survival models to liver allocation. *Liver Transpl* 2001;7:567-80.
9. Dharel N, Bajaj JS. Definition and nomenclature of hepatic encephalopathy. *J Clin Exp Hepatol* 2015 Mar;5(Suppl 1):S37-41
10. Angermayr B, Cejna M, Karnel F, et al. Child-Pugh versus MELD score in predicting survival in patients undergoing transjugular intrahepatic portosystemic shunt. *Gut* 2003; 52:879–85.
11. Samiullah S, Qasim R, Khalid S, Hussain BG, Mukhtair J, Akbar Y. Evaluation of creatininemodified Child-Pugh score for predicting short-term prognosis of patients

- with decompensated cirrhosis of liver as compare to original Child-Pugh score. *J Ayub Med Coll Abbotabad* 2009;21(2):64-7.
12. Malinchoc M, Kamath PS, Gordon FD, Peine CJ, Rank J, ter Borg PC. A model to predict poor survival in patients undergoing transjugular portosystemic intrahepatic portosystemic shunts. *Hepatology* 2000;31:864-71.
  13. Said A, Williams J, Holden J, Remington P, Gangnon R, Musat A, Lucey MR. Model of endstage liver disease score predicts mortality across a broad spectrum of liver disease. *J Hepatol* 2004;40:897-903.
  14. Martin AP, Bartels M, Hauss J, Fangmann J. Overview of the MELD score and the UNOS adult liver allocation system. *Transplant Proc* 2007;39:3169-74.
  15. Ravaioli M, Grazi GL, Ballardini G, et al. Liver transplantation with the Meld system: a prospective study from a single European center. *Am J Transplant* 2006;6:1572-7.
  16. Schepke M, Roth F, Fimmers R, Brensing KA, Sudhop T, Schild HH, Sauerbruch T. Comparison of MELD, Child-Pugh, and Emory model for the prediction of survival in patients undergoing transjugular intrahepatic portosystemic shunting. *Am J Gastroenterol* 2003;98:1167-74.
  17. Wiesner RH, McDiarmid SV, Kamath PS, Edwards EB, Malinchoc M, Kremers WK, et al. MELD and PELD: application on survival models to liver allocation. *Liver Transpl* 2001;7:567-80.
  18. Thanopoulou AC, Koskinas JS, Hadziyannis SJ. Spontaneous bacterial peritonitis (SBP): clinical, laboratory, and prognostic features. A single-center experience. *Eur J Intern Med* 2002;13(3):194-8.
  19. Oladimeji AA, Temi AP, Adekunle AE, Taiwo RH, Ayokunle DS. Prevalence of spontaneous bacterial peritonitis in liver cirrhosis with ascites. *Pan Afr Med J* 2013;15:128.
  20. Coral G, Mattos AA, Damo DF, Viégas AC. Prevalence and prognosis of spontaneous bacterial peritonitis. Experience in patients from a general hospital in Porto Alegre, RS, Brazil (1991-2000). *Arq Gastroenterol* 2002; 39(3):158-62. 1.
  21. Such J, Runyon BA. Spontaneous bacterial peritonitis. *Clin Infect Dis* 1998;27:669-74.
  22. Heo J, Seo YS, Yim HJ, et al. Clinical features and prognosis of spontaneous bacterial peritonitis in korean patients with liver cirrhosis: a multicenter retrospective study. *Gut Liver* 2009;3(3): 197-204.
  23. Kasztelan-Szczerbinska B, Slomka M, Celinski K, et al. Prevalence of spontaneous bacterial peritonitis in asymptomatic inpatients with decompensated liver cirrhosis – a pilot study. *Adv Med Sci* 2011;56(1):13-7.
  24. Haddad L, Conte TM, Ducatti L, et al. MELD Score is not related to spontaneous bacterial peritonitis. *Gastroenterol Res Pract* 2015;2015:270456.
  25. Zhang QB, Chen YT, Lion GD, Qian CC, Chen SJ, Huang KH. A combination of models for end-stage liver disease and cirrhosis-related complications to predict the prognosis of liver cirrhosis. *Clin Res Hepatol Gastroenterol* 2012;36:583-9.
  26. Obstein KL, Campbell MS, Reddy RK,



- et al. Association between model for end-stage liver disease and spontaneous bacterial peritonitis. *Am J Gastroenterol* 2007;102(12):2732-6.
27. Gayatri AA, Suryadharma IG, Purwadi N, Wibawa D. The relationship between a model of end stage liver disease score (MELD score) and the occurrence of spontaneous bacterial peritonitis in liver cirrhotic patients. *Acta Medica Indonesiana* 2007; 39(2): 75-78.
  28. Oey RC, van Buuren HR, de Jong DM, et al. Bacterascites: A study of clinical features, microbiological findings, and clinical significance. *Liver Int* 2018;38(12):2199-2209.
  29. Desai AP, Reau N, Reddy G, et al. Persistent spontaneous bacterial peritonitis: a common complication in patients with spontaneous bacterial peritonitis and a high score in the model for end-stage liver disease. *Ther Adv Gastroenterol* 2010;5(5):275-83.